Cost-effectiveness analysis shows tirzepatide 5 mg provides superior long-term value compared to dulaglutide through greater metabolic improvements and complication prevention.
Key findingCost-effectiveness analysis shows tirzepatide 5 mg provides superior long-term value compared to dul
What the researchers found
Cost-effectiveness analysis shows tirzepatide 5 mg provides superior long-term value compared to dulaglutide through greater metabolic improvements and complication prevention.
Why it matters
Relevant to peptide therapeutics.
The numbers in context
Tirzepatide 5 mg vs. dulaglutide 0.75 mg, both once weekly. 50-year time horizon. Based on SURPASS J-mono trial results.
How the study worked
In publication.
Who was studied
Adults with type 2 diabetes not achieving glycemic control on metformin in Japan
What this study cannot tell us
In publication.
How to read the evidence
Based on design.
When this study was published
Published in 2025.
The bigger picture
Advances peptide evidence.
Questions still open
- Long-term implications?
- Evidence comparison?
- Next steps?
Common questions
What does this mean?
How reliable?
Read the original research
The Long-Term Cost-Effectiveness of Tirzepatide 5 mg versus Dulaglutide 0.75 mg for the Treatment of People with Type 2 Diabetes in Japan.
Diabetes therapy : research, treatment and education of diabetes and related disorders, 16(3), 431-445
Citation
Aranishi, Toshihiko; Igarashi, Ataru; Hara, Kazuo; Osumili, Beatrice; Cai, Zhihong; Mizogaki, Aska; Sato, Manaka; Takeuchi, Masakazu; Minghetti, Alice; Hunt, Barnaby; Kadowaki, Takashi. (2025). The Long-Term Cost-Effectiveness of Tirzepatide 5 mg versus Dulaglutide 0.75 mg for the Treatment of People with Type 2 Diabetes in Japan.. Diabetes therapy : research, treatment and education of diabetes and related disorders, 16(3), 431-445. https://doi.org/10.1007/s13300-024-01675-7